CRF system and mood disorders

Journal of Chemical Neuroanatomy

Volumn 54, Issue , 2013, Pages 20-24

  Aubry, Jean Michel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antidepressant response; Bipolar disorders; CRF antagonists; Depression; Stress reactivity

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG PENETRATION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STRESS;

ANTIDEPRESSANT RESPONSE; BIPOLAR DISORDERS; CRF ANTAGONISTS; DEPRESSION; STRESS REACTIVITY;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MOOD DISORDERS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 84888429113     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2013.09.003     Document Type: Article

References (80)

1. Altman S., Haeri S., Cohen L.J., Ten A., Barron E., Galynker I.I., Duhamel K.N. Predictors of relapse in bipolar disorder: a review. J. Psychiatr. Pract. 2006, 12:269-282.
2. Antoni F.A. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr. Rev. 1986, 7:351-378.
3. Arato M., Banki C.M., Bissette G., Nemeroff C.B. Elevated CSF CRF in suicide victims. Biol. Psychiatry 1989, 25:355-359.
4. Aubry J.M., Bartanusz V., Jezova D., Belin D., Kiss J.Z. Single stress induces long-lasting elevations in vasopressin mRNA levels in CRF hypophysiotrophic neurones, but repeated stress is required to modify AVP immunoreactivity. J. Neuroendocrinol. 1999, 11:377-384.
5. Aubry J.M., Pozzoli G., Vale W.W. Chronic treatment with the antidepressant amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala. Neurosci. Lett. 1999, 266:197-200.
6. Banki C.M., Bissette G., Arato M., O'Connor L., Nemeroff C.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am. J. Psychiatry 1987, 144:873-877.
7. Banki C.M., Karmacsi L., Bissette G., Nemeroff C.B. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur. Neuropsychopharmacol. 1992, 2:107-113.
8. Becker K., Abraham A., Kindler J., Helmeke C., Braun K. Exposure to neonatal separation stress alters exploratory behavior and corticotropin releasing factor expression in neurons in the amygdala and hippocampus. Dev. Neurobiol. 2007, 67:617-629.
9. Behan D.P., Linton E.A., Lowry P.J. Isolation of the human plasma corticotrophin-releasing factor-binding protein. J. Endocrinol. 1989, 122:23-31.
10. Bhatnagar S., Dallman M. Neuroanatomical basis for facilitation of hypothalamic-pituitary-adrenal responses to a novel stressor after chronic stress. Neuroscience 1998, 84:1025-1039.
11. Binder E.B., Nemeroff C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry 2010, 15:574-588.
12. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003, 28:1328-1335.
13. Bittencourt J.C., Vaughan J., Arias C., Rissman R.A., Vale W.W., Sawchenko P.E. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J. Comp. Neurol. 1999, 415:285-312.
14. Bonne O., Gill J.M., Luckenbaugh D.A., Collins C., Owens M.J., Alesci S., Neumeister A., Yuan P., Kinkead B., Manji H.K., Charney D.S., Vythilingam M. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry 2011, 72:1124-1128.
15. Boorse G.C., Denver R.J. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen. Comp. Endocrinol. 2006, 146:9-18.
16. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., Whitfield H.J. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 1992, 572:117-125.
17. Brady L.S., Whitfield H.J., Fox R.J., Gold P.W., Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 1991, 87:831-837.
18. Brietzke E., Mansur R.B., Soczynska J., Powell A.M., McIntyre R.S. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:1-8.
19. Chalmers R.M., Robertson N., Kellar-Wood H., Compston D.A., Harding A.E. Sequence of the human homologue of a mitochondrially encoded murine transplantation antigen in patients with multiple sclerosis. J. Neurol. 1995, 242:332-334.
20. Chen Y.L., Braselton J., Forman J., Gallaschun R.J., Mansbach R., Schmidt A.W., Seeger T.F., Sprouse J.S., Tingley F.D., Winston E., Schulz D.W. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists. J. Med. Chem. 2008, 51:1377-1384.
21. Claes S., Villafuerte S., Forsgren T., Sluijs S., Del-Favero J., Adolfsson R., Van Broeckhoven C. The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden. Biol. Psychiatry 2003, 54:867-872.
22. Coric V., Feldman H.H., Oren D.A., Shekhar A., Pultz J., Dockens R.C., Wu X., Gentile K.A., Huang S.P., Emison E., Delmonte T., D'Souza B.B., Zimbroff D.L., Grebb J.A., Goddard A.W., Stock E.G. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress. Anxiety 2010, 27:417-425.
23. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 2002, 23:71-77.
24. De Bellis M.D., Gold P.W., Geracioti T.D., Listwak S.J., Kling M.A. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry 1993, 150:656-657.
25. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
26. Di Fabio R., St-Denis Y., Sabbatini F.M., Andreotti D., Arban R., Bernasconi G., Braggio S., Blaney F.E., Capelli A.M., Castiglioni E., Di Modugno E., Donati D., Fazzolari E., Ratti E., Feriani A., Contini S., Gentile G., Ghirlanda D., Provera S., Marchioro C., Roberts K.L., Mingardi A., Mattioli M., Nalin A., Pavone F., Spada S., Trist D.G., Worby A. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. J. Med. Chem. 2008, 51:7370-7379.
27. Donaldson C.J., Sutton S.W., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J.E., Vaughan J.M., Vale W.W. Cloning and characterization of human urocortin. Endocrinology 1996, 137:2167-2170. (erratum in Endocrinology 1996; 2137(2169):3896).
28. Falco A.M., Bergstrom H.C., Bachus S.E., Smith R.F. Persisting changes in basolateral amygdala mRNAs after chronic ethanol consumption. Physiol. Behav. 2009, 96:169-173.
29. Fernandez Macedo G.V., Cladouchos M.L., Sifonios L., Cassanelli P.M., Wikinski S. Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm. Psychopharmacology (Berl) 2013, 225:647-659.
30. Gehlert D.R., Shekhar A., Morin S.M., Hipskind P.A., Zink C., Gackenheimer S.L., Shaw J., Fitz S.D., Sajdyk T.J. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur. J. Pharmacol. 2005, 509:145-153.
31. Hartline K.M., Owens M.J., Nemeroff C.B. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Ann. N.Y. Acad. Sci. 1996, 780:96-105.
32. Hashimoto K., Nishiyama M., Tanaka Y., Noguchi T., Asaba K., Hossein P.N., Nishioka T., Makino S. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides 2004, 25:1711-1721.
33. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 1997, 71:15-21.
34. Herringa R.J., Nanda S.A., Hsu D.T., Roseboom P.H., Kalin N.H. The effects of acute stress on the regulation of central and basolateral amygdala CRF-binding protein gene expression. Brain Res. Mol. Brain Res. 2004, 131:17-25.
35. Herringa R.J., Roseboom P.H., Kalin N.H. Decreased amygdala CRF-binding protein mRNA in post-mortem tissue from male but not female bipolar and schizophrenic subjects. Neuropsychopharmacology 2006, 31:1822-1831.
36. Heuser I., Bissette G., Dettling M., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Nemeroff C.B., Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress. Anxiety 1998, 8:71-79.
37. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., Guzzi M.F., Parker E.M., Varty G.B. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol. Biochem. Behav. 2007, 86:431-440.
38. Horesh N., Iancu I. A comparison of life events in patients with unipolar disorder or bipolar disorder and controls. Compr. Psychiatry 2010, 51:157-164.
39. Kasahara M., Groenink L., Breuer M., Olivier B., Sarnyai Z. Altered behavioural adaptation in mice with neural corticotrophin-releasing factor overexpression. Genes Brain Behav. 2007, 6:598-607.
40. Kim S.J., Park S.H., Choi S.H., Moon B.H., Lee K.J., Kang S.W., Lee M.S., Chun B.G., Shin K.H. Effects of repeated tianeptine treatment on CRF mRNA expression in non-stressed and chronic mild stress-exposed rats. Neuropharmacology 2006, 50:824-833.
41. Koob G.F., Thatcher-Britton K. Stimulant and anxiogenic effects of corticotropin releasing factor. Prog. Clin. Biol. Res. 1985, 192:499-506.
42. Kozicz T., Tilburg-Ouwens D., Faludi G., Palkovits M., Roubos E. Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression. Neuroscience 2008, 152:1015-1023.
43. Lemos J.C., Wanat M.J., Smith J.S., Reyes B.A., Hollon N.G., Van Bockstaele E.J., Chavkin C., Phillips P.E. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature 2012, 490:402-406.
44. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7570-7575.
45. Licinio J., O'Kirwan F., Irizarry K., Merriman B., Thakur S., Jepson R., Lake S., Tantisira K.G., Weiss S.T., Wong M.L. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 2004, 9:1075-1082.
46. Linton E.A., Perkins A.V., Woods R.J., Eben F., Wolfe C.D., Behan D.P., Potter E., Vale W.W., Lowry P.J. Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy. J. Clin. Endocrinol. Metab. 1993, 76:260-262.
47. Lowry C.A., Hale M.W., Plant A., Windle R.J., Shanks N., Wood S.A., Ingram C.D., Renner K.J., Lightman S.L., Summers C.H. Fluoxetine inhibits corticotropin-releasing factor (CRF)-induced behavioural responses in rats. Stress 2009, 12:225-239.
48. Mansbach R.S., Brooks E.N., Chen Y.L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 1997, 323:21-26.
49. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 2004, 24:1478-1485.
50. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bedard T., Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol. Psychiatry 2006, 59:594-602.
51. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 1988, 45:577-579.
52. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
53. Overstreet D.H., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur. J. Pharmacol. 2004, 497:49-53.
54. Paez-Pereda M., Hausch F., Holsboer F. Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin. Investig. Drugs 2011, 20:519-535.
55. Post R.M., Weiss S.R. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 1996, 13:33-60.
56. Potter E., Behan D.P., Fischer W.H., Linton E.A., Lowry P.J., Vale W.W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991, 349:423-426.
57. Potter E., Behan D.P., Linton E.A., Lowry P.J., Sawchenko P.E., Vale W.W. The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4192-4196.
58. Potter E., Sutton S., Donaldson C., Chen R., Perrin M., Lewis K., Sawchenko P.E., Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8777-8781.
59. Raadsheer F.C., Hoogendijk W.J., Stam F.C., Tilders F.J., Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994, 60:436-444.
60. Refojo D., Schweizer M., Kuehne C., Ehrenberg S., Thoeringer C., Vogl A.M., Dedic N., Schumacher M., von Wolff G., Avrabos C., Touma C., Engblom D., Schutz G., Nave K.A., Eder M., Wotjak C.T., Sillaber I., Holsboer F., Wurst W., Deussing J.M. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 2011, 333:1903-1907.
61. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133:312-320.
62. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2843-2848.
63. Santibanez M., Gysling K., Forray M.I. Desipramine prevents the sustained increase in corticotropin-releasing hormone-like immunoreactivity induced by repeated immobilization stress in the rat central extended amygdala. J. Neurosci. Res. 2006, 84:1270-1281.
64. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
65. Stout S.C., Owens M.J., Nemeroff C.B. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J. Pharmacol. Exp. Ther. 2002, 300:1085-1092.
66. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 1998, 19:162-166.
67. Tsatsanis C., Dermitzaki E., Venihaki M., Chatzaki E., Minas V., Gravanis A., Margioris A.N. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell. Mol. Life Sci. 2007, 64:1638-1655.
68. Turnbull A.V., Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc. Soc. Exp. Biol. Med. 1997, 215:1-10.
69. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
70. Van Den Eede F., Venken T., Del-Favero J., Norrback K.F., Souery D., Nilsson L.G., Van den Bossche B., Hulstijn W., Sabbe B.G., Cosyns P., Mendlewicz J., Adolfsson R., Van Broeckhoven C., Claes S.J. Single nucleotide polymorphism analysis of corticotropin-releasing factor-binding protein gene in recurrent major depressive disorder. Psychiatry Res. 2007, 153:17-25.
71. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 2000, 428:191-212.
72. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-292.
73. Veith R.C., Lewis N., Langohr J.I., Murburg M.M., Ashleigh E.A., Castillo S., Peskind E.R., Pascualy M., Bissette G., Nemeroff C.B., et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res. 1993, 46:1-8.
74. Wasserman D., Wasserman J., Sokolowski M. Genetics of HPA-axis, depression and suicidality. Eur. Psychiatry 2010, 25:278-280.
75. Whitnall M.H., Smyth D., Gainer H. Vasopressin coexists in half of the corticotropin-releasing factor axons present in the external zone of the median eminence in normal rats. Neuroendocrinology 1987, 45:420-424.
76. Wong M.L., al-Shekhlee A., Bongiorno P.B., Esposito A., Khatri P., Sternberg E.M., Gold P.W., Licinio J. Localization of urocortin messenger RNA in rat brain and pituitary. Mol. Psychiatry 1996, 1:307-312.
77. Yamano M., Yuki H., Yasuda S., Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J. Pharmacol. Exp. Ther. 2000, 292:181-187.
78. Zmijewski M.A., Slominski A.T. Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim. Pol. 2010, 57:1-13.
79. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34:171-181.
80. Zohar I., Weinstock M. Differential effect of prenatal stress on the expression of corticotrophin-releasing hormone and its receptors in the hypothalamus and amygdala in male and female rats. J. Neuroendocrinol. 2011, 23:320-328.